F de Braud1, S Cascinu2, G Spitaleri3, K Pilz4, L Clementi5, D Liu4, P Sikken4, T De Pas3. 1. Director of New Drug Development Unit, European Institute of Oncology, Milan filippo.debraud@istitutotumori.mi.it. 2. Department of Medical Oncology, Polytechnic University of the Marche Region, Ancona. 3. Medical Oncology Unit of Respiratory Tract and Sarcomas, Division of New Drugs Development, European Institute of Oncology, Milan, Italy. 4. Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany. 5. Boehringer Ingelheim Italia S.p.A., Milan, Italy.
Abstract
BACKGROUND: Volasertib is a potent and selective cell-cycle kinase inhibitor that induces mitotic arrest and apoptosis by targeting Polo-like kinases. This study determined the maximum tolerated dose (MTD) and pharmacokinetics of volasertib combined with nintedanib, a potent and orally bioavailable triple angiokinase inhibitor, in patients with advanced solid tumors. PATIENTS AND METHODS: This open-label, dose-escalation trial recruited patients with advanced metastatic solid tumors following failure of conventional treatment (NCT01022853; Study 1230.7). Volasertib was administered by intravenous infusion over 2 h, starting at 100 mg in the first dose cohort. Nintedanib was administered orally at a dose of 200 mg twice daily. The first treatment cycle comprised 28 days (days 1-7 and days 9-28: nintedanib; day 8: volasertib). From cycle 2 onwards, volasertib was administered on day 1 of a 21-day cycle and nintedanib was administered days 2-21. The primary objective was the MTD of volasertib in combination with nintedanib. RESULTS: Thirty patients were treated. The MTD of volasertib plus fixed-dose nintedanib was 300 mg once every 3 weeks, the same as the recommended single-agent dose of volasertib in solid tumors. Two of 12 assessable patients treated with the MTD experienced dose-limiting toxicities [grade 3 increased alanine aminotransferase (ALT); grade 3 ALT increase and grade 3 increased aspartate aminotransferase]. Disease control [stable disease (SD)/partial response (PR)/complete response (CR)] was achieved in 18 patients (60%): 1 CR (breast cancer), 1 PR (nonsmall-cell lung cancer), and 16 patients with SD. Volasertib showed that multiexponential pharmacokinetic behavior and co-administration of nintedanib had no significant effects on its exposure. CONCLUSIONS: Volasertib could be combined with fixed-dose nintedanib at the recommended single-agent dose. At this dose, the combination had a manageable safety profile without unexpected or overlapping adverse events, and showed antitumor activity.
BACKGROUND:Volasertib is a potent and selective cell-cycle kinase inhibitor that induces mitotic arrest and apoptosis by targeting Polo-like kinases. This study determined the maximum tolerated dose (MTD) and pharmacokinetics of volasertib combined with nintedanib, a potent and orally bioavailable triple angiokinase inhibitor, in patients with advanced solid tumors. PATIENTS AND METHODS: This open-label, dose-escalation trial recruited patients with advanced metastatic solid tumors following failure of conventional treatment (NCT01022853; Study 1230.7). Volasertib was administered by intravenous infusion over 2 h, starting at 100 mg in the first dose cohort. Nintedanib was administered orally at a dose of 200 mg twice daily. The first treatment cycle comprised 28 days (days 1-7 and days 9-28: nintedanib; day 8: volasertib). From cycle 2 onwards, volasertib was administered on day 1 of a 21-day cycle and nintedanib was administered days 2-21. The primary objective was the MTD of volasertib in combination with nintedanib. RESULTS: Thirty patients were treated. The MTD of volasertib plus fixed-dose nintedanib was 300 mg once every 3 weeks, the same as the recommended single-agent dose of volasertib in solid tumors. Two of 12 assessable patients treated with the MTD experienced dose-limiting toxicities [grade 3 increased alanine aminotransferase (ALT); grade 3 ALT increase and grade 3 increased aspartate aminotransferase]. Disease control [stable disease (SD)/partial response (PR)/complete response (CR)] was achieved in 18 patients (60%): 1 CR (breast cancer), 1 PR (nonsmall-cell lung cancer), and 16 patients with SD. Volasertib showed that multiexponential pharmacokinetic behavior and co-administration of nintedanib had no significant effects on its exposure. CONCLUSIONS:Volasertib could be combined with fixed-dose nintedanib at the recommended single-agent dose. At this dose, the combination had a manageable safety profile without unexpected or overlapping adverse events, and showed antitumor activity.
Authors: Moataz Reda; Worapol Ngamcherdtrakul; Shenda Gu; Daniel S Bejan; Natnaree Siriwon; Joe W Gray; Wassana Yantasee Journal: Cancer Lett Date: 2019-09-26 Impact factor: 8.679
Authors: Jankiben R Patel; Prasad Thangavelu; Renee M Terrell; Bridg'ette Israel; Arindam Basu Sarkar; A Michael Davidson; Kun Zhang; Rahul Khupse; Syreeta L Tilghman Journal: Biomolecules Date: 2022-03-31
Authors: Sarah Alexandrou; Sandra Marie George; Christopher John Ormandy; Elgene Lim; Samantha Richelle Oakes; C Elizabeth Caldon Journal: Int J Mol Sci Date: 2019-02-04 Impact factor: 5.923
Authors: Antonio Giordano; Yueying Liu; Kent Armeson; Yeonhee Park; Maya Ridinger; Mark Erlander; James Reuben; Carolyn Britten; Christiana Kappler; Elizabeth Yeh; Stephen Ethier Journal: PLoS One Date: 2019-11-21 Impact factor: 3.240